loading
前日終値:
$54.97
開ける:
$54.64
24時間の取引高:
1.36M
Relative Volume:
0.69
時価総額:
$11.02B
収益:
$2.95B
当期純損益:
$523.88M
株価収益率:
20.69
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
+1.85%
1か月 パフォーマンス:
-4.08%
6か月 パフォーマンス:
-15.26%
1年 パフォーマンス:
-32.18%
1日の値動き範囲:
Value
$54.62
$56.66
1週間の範囲:
Value
$53.76
$56.66
52週間の値動き範囲:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1175)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,040
Name
Twitter
Name
次回の収益日
2024-10-29
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

BMRN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
55.68 11.02B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
451.73 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.43 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.39 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
547.40 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.71 28.51B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025
pulisher
Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025
pulisher
Jun 09, 2025

Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com

Jun 09, 2025
pulisher
Jun 05, 2025

Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool

Jun 05, 2025
pulisher
Jun 05, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Marin Awareness Walk Draws Over 100 Community Members - Patch

Jun 04, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans - Investing.com

Jun 02, 2025
pulisher
May 30, 2025

BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews

May 30, 2025
pulisher
May 30, 2025

The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN

May 29, 2025
pulisher
May 28, 2025

Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com

May 28, 2025
pulisher
May 28, 2025

Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 - Investing.com

May 27, 2025
pulisher
May 26, 2025

Phenylktonuria Treatment Market Overall Study Report - openPR.com

May 26, 2025
pulisher
May 26, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance

May 26, 2025
pulisher
May 25, 2025

BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com

May 25, 2025
pulisher
May 24, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN

May 24, 2025
pulisher
May 24, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 24, 2025
pulisher
May 23, 2025

Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media

May 23, 2025
pulisher
May 22, 2025

BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks

May 22, 2025
pulisher
May 22, 2025

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo

May 22, 2025
pulisher
May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025
pulisher
May 21, 2025

6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World

May 21, 2025
pulisher
May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025
pulisher
May 20, 2025

Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Is this European biotech’s moment? — a BioCentury podcast - biocentury.com

May 19, 2025
pulisher
May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025
pulisher
May 19, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 19, 2025
pulisher
May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

May 19, 2025
pulisher
May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025
pulisher
May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.77
price up icon 0.51%
$35.85
price down icon 0.61%
$21.20
price down icon 0.47%
$97.77
price down icon 2.96%
$107.97
price up icon 1.45%
biotechnology ONC
$243.70
price up icon 0.63%
大文字化:     |  ボリューム (24 時間):